The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).
Paul Haluska
Consultant or Advisory Role - ImClone Systems (U)
Research Funding - GlaxoSmithKline; ImClone Systems
Albert M. Bernath
No relevant relationships to disclose
Karla V. Ballman
No relevant relationships to disclose
Amylou C. Dueck
No relevant relationships to disclose
Hannah M. Linden
No relevant relationships to disclose
Matthew P. Goetz
No relevant relationships to disclose
Donald W. Northfelt
No relevant relationships to disclose
Xiaonan Hou
No relevant relationships to disclose
Kathleen S. Tenner
No relevant relationships to disclose
Piyawan Tienchaiananda
No relevant relationships to disclose
Lynn M. Flickinger
No relevant relationships to disclose
Beiyun Chen
No relevant relationships to disclose
Helen X. Chen
No relevant relationships to disclose
Wilma L. Lingle
No relevant relationships to disclose
Christine M. Pellegrino
No relevant relationships to disclose
Robert W. Sponzo
No relevant relationships to disclose
Monica Madden Reinholz
No relevant relationships to disclose
Edith A. Perez
No relevant relationships to disclose